Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Use of new exosomes for the diagnosis and treatment of neoplasias

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20200717001
Publicado:
05/08/2020
Caducidad:
06/08/2021
Resumen:
A Spanish research center has discovered the use of new extracellular vesicles (EVs), preferably exosomes for the diagnosis and/or monitoring of tumors as well as their treatment. These vesicles are easy to prepare and obtain, in combination with radioactive isotopes. They are looking for technical, research or license agreements.

Details

Tittle:
Use of new exosomes for the diagnosis and treatment of neoplasias
Summary:
A Spanish research center has discovered the use of new extracellular vesicles (EVs), preferably exosomes for the diagnosis and/or monitoring of tumors as well as their treatment. These vesicles are easy to prepare and obtain, in combination with radioactive isotopes. They are looking for technical, research or license agreements.
Description:
The Na+/I- transporter (NIS) has been used for molecular imaging (positron emission tomography, PET, or single-photon emission computed tomography, SPECT, depending on the isotope used) or as a therapeutic agent if the isotope used is a high-energy isotope (e.g. therapy with radioiodine 131I). But one of the remaining problems is how to target this gene specifically to the tumor area.
The expression of NIS in exosomes and the accumulation of these in neoplasias can serve (i) to visualize neoplasias and (ii) for therapy. These exosomes are able to reach the tumour areas when they are injected intravenously. This new exosomes have shown a 50% reduction in tumour growth in trials.

The Spanish research center is seeking for companies preferably from the pharmaceutical, biotechnology and molecular biology sectors, to establish technical cooperation or license agreements. Besides, they will be also open to research cooperation agreements with public and private institutions of the same sector for building consortia.
Advantages and Innovations:
- Easy to prepare and obtain.
- Priority patent application (April 2020).
- High tropism towards tumor areas.
- Fewer side effects.
- Greater specificity.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Priority patent application (April 2020).

Partner sought

Type and Role of Partner Sought:
The research center is looking for companies interested in license and technical cooperation agreements for the development of the technology, preferably from the pharmaceutical, biotechnology, and molecular biology sectors.

Although it is not the client´s priority, they are also open to research cooperation agreements and technical cooperation agreements with public and private institutions for possible research projects in the same topics already mentioned.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología